Alterity Therapeutics Limited (ATHE)
NASDAQ: ATHE · Real-Time Price · USD
3.420
+0.060 (1.79%)
At close: Jan 17, 2025, 4:00 PM
3.480
+0.060 (1.75%)
After-hours: Jan 17, 2025, 5:01 PM EST
Alterity Therapeutics Employees
Alterity Therapeutics had 10 employees as of June 30, 2024. The number of employees decreased by 1 or -9.09% compared to the previous year.
Employees
10
Change (1Y)
-1
Growth (1Y)
-9.09%
Revenue / Employee
$268,167
Profits / Employee
-$1,275,918
Market Cap
28.10M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
ATHE News
- 11 days ago - Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones - GlobeNewsWire
- 6 weeks ago - Alterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in Early-Stage Multiple System Atrophy - GlobeNewsWire
- 2 months ago - Alterity Therapeutics Appoints Abby Macnish Niven as Company Secretary - GlobeNewsWire
- 2 months ago - Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium - GlobeNewsWire
- 2 months ago - Alterity Therapeutics Announces New Publication Describing Novel Mechanism of Action for ATH434 - GlobeNewsWire
- 2 months ago - Appendix 4C – Q1 FY25 Quarterly Cash Flow Report - GlobeNewsWire
- 3 months ago - Alterity Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on 17 October 2024 - GlobeNewsWire
- 3 months ago - Alterity Therapeutics Announces Presentation of New Data Describing Neuroprotection of ATH434 at Neuroscience Meeting - GlobeNewsWire